Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 87)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.721
Gesamt: 345.721
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: SLS
1,6300
USD
+5,84 %
+0,0900 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 384,00 | +20,00 | |
| 0,5800 | +19,34 | |
| 5,9050 | +17,86 | |
| 111,15 | +16,77 | |
| 1,7000 | +13,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 14,510 | -32,32 | |
| 71,33 | -33,92 | |
| 3,6400 | -38,62 | |
| 1.160,00 | -42,00 | |
| 0,7000 | -61,85 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 52.437.951 von Blackwater01 am 19.05.16 11:26:37Keine Ahnung ob alles stimmt, aber der folgende Threadüberschrift drüben auf Yahoo (im Bezug auf dem gestrigen Handelssitzung hat mir sehr gut gefallen vorhin
50%+ Huge Short Volume Today & Gale was up 12% Massively Bullish / Shorts trying to hold the PPS but There is No Escape/ Get 'Em Cheap Now
FBP Proved Very Durable in the Optimally Dosed group - a 200% Increase in Progression Free survival
- these are the results Fast Track Designation and early FDA approval Are made for - FBP very Valuable
- Galena Will put a full on Press Release to announce these two year results
- This data will be published in Poster Format at ASCO June 6
- Galena will also announce the VADIS Trial in collaboration with the NCI by the end of June
- Gale will also Officially settle all the pending litigation June 23rd
- Gale present AnagrelideCR data at ASH in June
and the biggest kahuna
- Neuvax Phase 3 PRESENT Data IDMC recommendation by the End of JUNE
This is a good time to get invested in GALE - Shorts have nowhere to go
...we will see
50%+ Huge Short Volume Today & Gale was up 12% Massively Bullish / Shorts trying to hold the PPS but There is No Escape/ Get 'Em Cheap Now
FBP Proved Very Durable in the Optimally Dosed group - a 200% Increase in Progression Free survival
- these are the results Fast Track Designation and early FDA approval Are made for - FBP very Valuable
- Galena Will put a full on Press Release to announce these two year results
- This data will be published in Poster Format at ASCO June 6
- Galena will also announce the VADIS Trial in collaboration with the NCI by the end of June
- Gale will also Officially settle all the pending litigation June 23rd
- Gale present AnagrelideCR data at ASH in June
and the biggest kahuna
- Neuvax Phase 3 PRESENT Data IDMC recommendation by the End of JUNE
This is a good time to get invested in GALE - Shorts have nowhere to go
...we will see
Antwort auf Beitrag Nr.: 52.437.741 von Growth2012 am 19.05.16 11:06:57
Danke....und gerne...bei der Seite hat man schnell alle relevanten Indikatoren auf einen Blick
Wenn es heute zu keinem Abverkauf im Handelsverlauf in USA kommt....bin ich seehr zuversichtlich das wir einer stabilen Trendwende entgegen sehen dürfen bei GALE.
Ich hoffe das die 2$ Marke bald.....gerissen werden wird !
Zitat von Growth2012: @Blackwater, klasse Seite (die Chartdarstellung gefällt mir außerordentlich gut), Danke fürs reinstellen-Wilkommen im Bord, und am Board
Danke....und gerne...bei der Seite hat man schnell alle relevanten Indikatoren auf einen Blick
Wenn es heute zu keinem Abverkauf im Handelsverlauf in USA kommt....bin ich seehr zuversichtlich das wir einer stabilen Trendwende entgegen sehen dürfen bei GALE.
Ich hoffe das die 2$ Marke bald.....gerissen werden wird !
Antwort auf Beitrag Nr.: 52.435.692 von Blackwater01 am 19.05.16 07:33:17@Blackwater, klasse Seite (die Chartdarstellung gefällt mir außerordentlich gut), Danke fürs reinstellen-Wilkommen im Bord, und am Board
Guten Morgen in die Runde!
Gale hat deren Ovarian Cancer Solution (301) gesternabend auf der ASCO convention vorgestellt, tja, wenn man die anschließende Kursverlauf etwas näher betrachtet, dann könnte man annehmen dass der Vortrag einige Teilnehmern wohl sehr gut gefallen hat
Galena Biopharma (GALE) to Present the GALE-301 Phase 1/2a Primary Analysis at ASCO
http://www.streetinsider.com/Corporate+News//Galena+Biopharm…
Ein paar interessanter statistiken im Bereich Gynecologic Cancer aus dem Beitrag anbei....
About Ovarian/Endometrial Cancers
New cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 – 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%.
Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.
New cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 – 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.
Gale hat deren Ovarian Cancer Solution (301) gesternabend auf der ASCO convention vorgestellt, tja, wenn man die anschließende Kursverlauf etwas näher betrachtet, dann könnte man annehmen dass der Vortrag einige Teilnehmern wohl sehr gut gefallen hat
Galena Biopharma (GALE) to Present the GALE-301 Phase 1/2a Primary Analysis at ASCO
http://www.streetinsider.com/Corporate+News//Galena+Biopharm…
Ein paar interessanter statistiken im Bereich Gynecologic Cancer aus dem Beitrag anbei....
About Ovarian/Endometrial Cancers
New cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for 2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated 14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime (2010 – 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for women with ovarian cancer is 45.6%.
Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse. Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60% to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains incurable.
New cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their lifetime (2010 – 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year survivorship for women with endometrial cancer is 81.7%.
Antwort auf Beitrag Nr.: 52.435.677 von Blackwater01 am 19.05.16 07:31:48
Hier den Link richtig eingestellt :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Zitat von Blackwater01: Guten Morgen.....ich halte auch seid ein paar Tagen eine größere Posi von Gale im Depot.
Charttechnisch sieht es derzeit sehr gut aus :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Sollten sich der grüne Verlauf heute weiter bestätigen....unter hohem Volumen...vermute ich stark..das es zum glattstellen der Kurzen kommen wird...
Ich hoffe das die Trials gut sein werden.....wenn es zu einem Buyout kommen sollte....hätte ich bei dem Marktpotenzial hier.....auch keinen Einwand
Good Luck den Investierten.....(Longs !)
Hier den Link richtig eingestellt :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Trading Spotlight
Guten Morgen.....ich halte auch seid ein paar Tagen eine größere Posi von Gale im Depot.
Charttechnisch sieht es derzeit sehr gut aus :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Sollten sich der grüne Verlauf heute weiter bestätigen....unter hohem Volumen...vermute ich stark..das es zum glattstellen der Kurzen kommen wird...
Ich hoffe das die Trials gut sein werden.....wenn es zu einem Buyout kommen sollte....hätte ich bei dem Marktpotenzial hier.....auch keinen Einwand
Good Luck den Investierten.....(Longs !)
Charttechnisch sieht es derzeit sehr gut aus :
http://www.stockta.com/cgi-bin/analysis.pl?symb=GALE&cobrand…
Sollten sich der grüne Verlauf heute weiter bestätigen....unter hohem Volumen...vermute ich stark..das es zum glattstellen der Kurzen kommen wird...
Ich hoffe das die Trials gut sein werden.....wenn es zu einem Buyout kommen sollte....hätte ich bei dem Marktpotenzial hier.....auch keinen Einwand
Good Luck den Investierten.....(Longs !)
Antwort auf Beitrag Nr.: 52.435.050 von Growth2012 am 18.05.16 23:30:56Hi Growht. Das sind aber nicht die Ergebnisse die Ende Q2 präsentiert werden sollten, oder?
Möchte hier nicht NUR ShortSqueeze haben sondern auch nachhaltig investieren und bleiben.
Gruss
Andy
PS: ich habe richtige Schadensfreude gegeüber Shortgemeinde. Meine Gründe kennt ihr.
Möchte hier nicht NUR ShortSqueeze haben sondern auch nachhaltig investieren und bleiben.
Gruss
Andy
PS: ich habe richtige Schadensfreude gegeüber Shortgemeinde. Meine Gründe kennt ihr.
Oh dear, shorts are as of now "officially" in the shit....
Results are In - You should have bought/covered today!
-yr DFS was 41.4% in VG v 36% in CG (p= 0.70); however, in the OPT group, the 2-yr DFS was 64.3% v 36% in the CG (p= 0.03). Conclusions: This phase I/IIa trial utilizing E39 and booster inoculations to prevent recurrence in EC and OC pts has shown the vaccine to be safe and immunogenic. These results demonstrate the potential clinical benefit of E39 at the 1000mcg dose to prevent recurrence and that boosters may sustain this effect. These promising results will be further evaluated in a larger clinical trial. Clinical trial information: NCT01580696
After Hours : 1.53 Up 0.05 (3.38%)...to start with
Results are In - You should have bought/covered today!
-yr DFS was 41.4% in VG v 36% in CG (p= 0.70); however, in the OPT group, the 2-yr DFS was 64.3% v 36% in the CG (p= 0.03). Conclusions: This phase I/IIa trial utilizing E39 and booster inoculations to prevent recurrence in EC and OC pts has shown the vaccine to be safe and immunogenic. These results demonstrate the potential clinical benefit of E39 at the 1000mcg dose to prevent recurrence and that boosters may sustain this effect. These promising results will be further evaluated in a larger clinical trial. Clinical trial information: NCT01580696
After Hours : 1.53 Up 0.05 (3.38%)...to start with
Antwort auf Beitrag Nr.: 52.426.587 von kusbas am 17.05.16 23:20:35@kusbas, gut gemeinte Rat, lass es doch lieber sein mit dem persönlichen 
Durchsuchen
